Blab News
South Africa Launches Long-Acting HIV Prevention Shot Amid Growing Demand and Limited Supply
On Friday, June 5 2026, South Africa rolled out a new twice‑yearly injectable HIV prevention drug, lenacapavir, in a high‑profile ceremony that underscored the country’s relentless battle against the world’s largest HIV epidemic.
The launch follows a $72 million government pledge to broaden access to the medication. Lenacapavir, sold under the brand name Yeztugo by Gilead Sciences, is a long‑acting antiretroviral that requires only two subcutaneous injections per year. The drug received U.S. Food and Drug Administration approval in October 2025 and has demonstrated near‑complete protection in clinical trials.
The timing of the rollout resonates with the story of 19‑year‑old Olwam Plaatjie from Secunda. Plaatjie began using pre‑exposure prophylaxis (PrEP) at age 16, after watching family members and neighbors fall victim to HIV. Her experience illustrates the personal stakes that drive the national rollout.
The Department of Health has earmarked 23 high‑incidence districts across six provinces for the initial distribution, targeting roughly 450 000 people at high risk. The plan is to make the injections available in 360 clinics by February 2027, pending final regulatory approval.
Activists and community groups, however, have voiced concerns that the first allocation falls far short of the number of people who could benefit, especially in township areas where prevalence remains stubbornly high. A report from the South African National AIDS Council highlighted the gap between supply and need.
South Africa’s HIV statistics underscore the urgency of the new program. As of 2022, an estimated 8 million South Africans—about 13.9 % of the population—were living with HIV. The adult prevalence rate for ages 15 to 49 was 19 % in 2019, ranking fourth worldwide.
Lenacapavir is a key component of the National Strategic Plan for HIV, TB and STIs 2023‑2028, which aligns with the Global HIV Prevention Roadmap 2025. International partners, including UNAIDS and the World Health Organization, have praised the drug’s potential to improve adherence by eliminating the need for monthly pill‑taking.
Yet funding challenges loom. U.S. aid cuts announced in 2026 have reduced support for low‑ and middle‑income countries, potentially slowing the pace of distribution. The global partnership that set lenacapavir’s price at US$40 per patient annually in 120 countries may need to adjust to the new funding environment.
South Africa’s government has pledged to monitor the rollout closely. Health officials will track infection rates and adherence data to evaluate the program’s impact, and plans are in place to expand coverage as additional supplies arrive.
In the coming weeks, the focus will shift to scaling up distribution, training healthcare workers, and engaging communities to raise awareness about the new prevention option. Success will hinge on sustained funding, community acceptance, and the ability to reach the most vulnerable populations.
The launch of lenacapavir marks a significant milestone in South Africa’s fight against HIV, offering a more convenient and potentially more effective prevention tool. Whether the limited initial supply can meet the high demand remains to be seen, but the program represents a concrete step toward reducing new infections in a country that has long battled the epidemic.
The launch follows a $72 million government pledge to broaden access to the medication. Lenacapavir, sold under the brand name Yeztugo by Gilead Sciences, is a long‑acting antiretroviral that requires only two subcutaneous injections per year. The drug received U.S. Food and Drug Administration approval in October 2025 and has demonstrated near‑complete protection in clinical trials.
The timing of the rollout resonates with the story of 19‑year‑old Olwam Plaatjie from Secunda. Plaatjie began using pre‑exposure prophylaxis (PrEP) at age 16, after watching family members and neighbors fall victim to HIV. Her experience illustrates the personal stakes that drive the national rollout.
The Department of Health has earmarked 23 high‑incidence districts across six provinces for the initial distribution, targeting roughly 450 000 people at high risk. The plan is to make the injections available in 360 clinics by February 2027, pending final regulatory approval.
Activists and community groups, however, have voiced concerns that the first allocation falls far short of the number of people who could benefit, especially in township areas where prevalence remains stubbornly high. A report from the South African National AIDS Council highlighted the gap between supply and need.
South Africa’s HIV statistics underscore the urgency of the new program. As of 2022, an estimated 8 million South Africans—about 13.9 % of the population—were living with HIV. The adult prevalence rate for ages 15 to 49 was 19 % in 2019, ranking fourth worldwide.
Lenacapavir is a key component of the National Strategic Plan for HIV, TB and STIs 2023‑2028, which aligns with the Global HIV Prevention Roadmap 2025. International partners, including UNAIDS and the World Health Organization, have praised the drug’s potential to improve adherence by eliminating the need for monthly pill‑taking.
Yet funding challenges loom. U.S. aid cuts announced in 2026 have reduced support for low‑ and middle‑income countries, potentially slowing the pace of distribution. The global partnership that set lenacapavir’s price at US$40 per patient annually in 120 countries may need to adjust to the new funding environment.
South Africa’s government has pledged to monitor the rollout closely. Health officials will track infection rates and adherence data to evaluate the program’s impact, and plans are in place to expand coverage as additional supplies arrive.
In the coming weeks, the focus will shift to scaling up distribution, training healthcare workers, and engaging communities to raise awareness about the new prevention option. Success will hinge on sustained funding, community acceptance, and the ability to reach the most vulnerable populations.
The launch of lenacapavir marks a significant milestone in South Africa’s fight against HIV, offering a more convenient and potentially more effective prevention tool. Whether the limited initial supply can meet the high demand remains to be seen, but the program represents a concrete step toward reducing new infections in a country that has long battled the epidemic.
